Open Account
العربية
Open Account

Sanofi's Amlitelimab Shows Clinically Meaningful Efficacy In Phase 2 Asthma Study, Phase 3 Program In Planning

Sanofi Sponsored ADR +0.86% Pre

Sanofi Sponsored ADR

SNY

0.00

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

  • New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma
  • Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma
  • Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via